Free Trial

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra logo with Medical background

Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $252.70, for a total value of $151,620.00. Following the completion of the sale, the executive vice president owned 66,057 shares of the company's stock, valued at approximately $16,692,603.90. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Johanna Roberts also recently made the following trade(s):

  • On Monday, June 2nd, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $258.17, for a total value of $154,902.00.
  • On Monday, May 12th, Johanna Roberts sold 900 shares of Penumbra stock. The shares were sold at an average price of $298.55, for a total value of $268,695.00.
  • On Thursday, April 24th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $300.01, for a total value of $180,006.00.

Penumbra Stock Performance

PEN stock traded up $0.80 during midday trading on Friday, hitting $250.54. The company's stock had a trading volume of 233,847 shares, compared to its average volume of 453,066. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The stock has a market cap of $9.70 billion, a price-to-earnings ratio of 236.36, a PEG ratio of 2.23 and a beta of 0.47. The stock's 50-day moving average price is $270.14 and its 200 day moving average price is $268.03. The company has a quick ratio of 3.68, a current ratio of 6.30 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. Penumbra had a net margin of 3.41% and a return on equity of 11.14%. The company had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. During the same period in the previous year, the firm earned $0.41 EPS. The firm's quarterly revenue was up 16.3% on a year-over-year basis. On average, equities analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Wall Street Zen raised shares of Penumbra from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 14th. BTIG Research restated a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Bank of America started coverage on shares of Penumbra in a research report on Friday, March 14th. They issued a "buy" rating and a $320.00 price target on the stock. Finally, Robert W. Baird boosted their price objective on Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Penumbra has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.

Get Our Latest Research Report on Penumbra

Institutional Investors Weigh In On Penumbra

Several large investors have recently modified their holdings of PEN. Vanguard Group Inc. grew its holdings in Penumbra by 0.7% during the first quarter. Vanguard Group Inc. now owns 3,675,349 shares of the company's stock valued at $982,825,000 after purchasing an additional 24,727 shares during the period. RTW Investments LP lifted its position in shares of Penumbra by 8.4% during the 4th quarter. RTW Investments LP now owns 862,450 shares of the company's stock valued at $204,815,000 after buying an additional 66,700 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Penumbra by 47.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company's stock worth $167,913,000 after acquiring an additional 227,506 shares during the period. JPMorgan Chase & Co. increased its holdings in Penumbra by 437.0% in the 1st quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company's stock worth $188,159,000 after acquiring an additional 572,606 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Penumbra by 19.9% in the 4th quarter. Bank of America Corp DE now owns 346,528 shares of the company's stock valued at $82,293,000 after acquiring an additional 57,421 shares during the period. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Company Profile

(Get Free Report)

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

Featured Stories

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Should You Invest $1,000 in Penumbra Right Now?

Before you consider Penumbra, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.

While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines